For the second time in 6 months, the Centers for Medicare & Medicaid Services officials have revised readmission penalties for hospitals. In doing so, approximately 1200 hospitals are now subject to lesser penalties.
For the second time in 6 months, the Centers for Medicare & Medicaid Services (CMS) officials have revised readmission penalties for hospitals. In doing so, approximately 1200 hospitals are now subject to lesser penalties.
The new corrections include decreased penalties for 1246 hospitals and increased penalties for 226 hospitals, resulting in a total of $280 million in penalties, which is approximately $10 million less than previously calculated. Kaiser Health News also released the following information following an analysis of the new data:
According to Jonathan Blum, Acting Principal Deputy Administrator and Director, Center for Medicare and CMS, stated that “This decrease is an early sign that our payment and delivery reforms are having an impact.” Kaiser Health News adds that “Under the program, the government is looking at the number of heart attack, heart failure, and pneumonia patients who return to the hospital within 30 days of discharge,” and that “hospitals with more readmissions than Medicare expected given their mix of patients are penalized by losing up to 1% of their regular payments.”
Around the Web
Medicare Revises Readmissions Penalties — Again [Kaiser Health News]
CMS Revises Hospitals' Readmission Penalties for the Second Time [Becker’s Hospital Review]
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More